US Drug Recall Register

FDA Drug Recalls

1,709 recalls · Class III, newest first

Class III · Low risk Terminated

Tadalafil SR 7 mg Capsules packed in 8

Reason Labeling Not Elsewhere Classified: Misbranding.

Right Value Drug Stores, Inc. NDC 99999-9970-88 D-0242-2019
Class III · Low risk Terminated

Progesterone SR 200 mg Capsules

Reason Labeling Not Elsewhere Classified: Misbranding.

Right Value Drug Stores, Inc. NDC 99999-0018-74 D-0241-2019
Class III · Low risk Terminated

Progesterone SR 100 mg Capsules

Reason Labeling Not Elsewhere Classified: Misbranding.

Right Value Drug Stores, Inc. NDC 99999-0104-55 D-0240-2019
Class III · Low risk Terminated

Altavera Levonorgestrel and Ethinyl Estradiol Tablets

Reason Labeling: Not Elsewhere Classified: mislabeling of the Altavera generic name on the packaging component that may cause confusion.

Xiromed LLC NDC 70700-116-85 D-0016-2019
Class III · Low risk Terminated

treatNOW ABILIFY

Reason Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Otsuka Pharmaceutical Development & Commercialization, Inc. D-0018-2019
Class III · Low risk Terminated

treatNOW ABILIFY

Reason Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Otsuka Pharmaceutical Development & Commercialization, Inc. D-0017-2019
Class III · Low risk Terminated

Fenofibrate Tablets

Reason Presence of Foreign Tablet/Capsule: A foreign identified as Valacyclovir tablet 500 mg was co-mingled in a bottle containing Fenofibrate Tablets, USP 145 mg.

Hetero Labs, Ltd. - Unit III NDC 31722-596-90 D-1211-2018
Class III · Low risk Terminated

Zoledronic Acid Injection

Reason Failed Impurities/Degradation Specifications: OOS for unknown impurities.

Dr. Reddy's Laboratories, Inc. NDC 43598-331-11 D-0104-2019
Class III · Low risk Terminated

Zoledronic Acid Injection

Reason Failed Impurities/Degradation Specifications: OOS for unknown impurities.

Dr. Reddy's Laboratories, Inc. NDC 55111-688-52 D-0103-2019
Class III · Low risk Terminated

Bupropion Hydrochloride ER Tablets

Reason Failed impurities/ degradation specifications: Out-of-specification results were observed in the meta-chlorobenzoic acid impurity in batches 18 months or older from date of manufacture in the 90 count bottle size.

InvaGen Pharmaceuticals, Inc. NDC 69097-875-05 D-1212-2018
Class III · Low risk Terminated

Pramipexole dihydrochloride extended release tablets

Reason Failed impurities/degradation specifications: Finished product contain a known product impurity about current specification levels.

Par Pharmaceutical, Inc. NDC 10370-252-11 D-1185-2018
Class III · Low risk Terminated

Argatroban Injection

Reason Failed Impurities/Degradation Specifications; Out of specification stability testing results at the 18 month time point

Pfizer Inc. D-1184-2018
Class III · Low risk Terminated

MethylPREDNISolone Tablets

Reason Failed Stability Specifications: An out-of-specification result was obtained during 18-month stability testing for assay.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-001-03 D-1205-2018
Class III · Low risk Terminated

Levonorgestrel and Ethinyl Estradiol Tablets

Reason Labeling: Not Elsewhere Classified-Incorrect NDC and product name identified on blister packs.

Mylan Pharmaceuticals Inc. NDC 0378-7281-53 D-0025-2019
Class III · Low risk Terminated

Morphine Sulfate Extended-Release Tablets

Reason Failed Impurities/Degradation Specifications: Morphine Sulfate Extended Release Tablets are being recalled due to out of Specification Result noticed for Morphinone Sulfate impurity during 3 month stability analysis and during retain testing.

Lupin Somerset NDC 43386-541-01 D-1214-2018
Class III · Low risk Terminated

Oxycodone and Acetaminophen Tablets

Reason Labeling: Incorrect or Missing Lot and/or Exp Date: Lot FG10517 is mislabeled on the primary container with Lot FG01517, shipper labels and invoices contain the correct lot number of FG10517.

Mayne Pharma Inc NDC 68308-841-01 D-1129-2018
Class III · Low risk Terminated

Diltiazem HCl Extended-release Capsules

Reason Failed Impurities/Degradation Specifications; out of specification results for related compound per the manufacturer

Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-947-08 D-1112-2018
Class III · Low risk Terminated

Valsartan Tablets USP

Reason Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-363-90 D-1106-2018
Class III · Low risk Terminated

Valsartan Tablets USP

Reason Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-362-90 D-1105-2018
Class III · Low risk Terminated

Valsartan Tablets USP

Reason Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-361-90 D-1104-2018
Class III · Low risk Terminated

Valsartan Tablets USP

Reason Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-360-30 D-1103-2018
Class III · Low risk Terminated

Contrave

Reason Defective Container: Customer complaints of punctures in the bottle.

Orexigen Therapeutics, Inc. NDC 51267-890-99 D-1099-2018
Class III · Low risk Terminated

Azelastine HCl Ophthalmic Solution 0.05%

Reason Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide

Akorn, Inc. NDC 17478-718-10 D-1168-2018